Elite Pharmaceuticals announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. For the twelve months ending August 31, 2022, the dopamine agonist had total US sales of approximately $12 million, according to IQVIA data.
Published first on TheFly